Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study

Daniela Gaglio, Silvia Valtorta, Marilena Ripamonti, Marcella Bonanomi, Chiara Damiani, Sergio Todde, Alfredo Simone Negri, Francesca Sanvito, Fabrizia Mastroianni, Antonella Di Campli, Gabriele Turacchio, Giuseppe Di Grigoli, Sara Belloli, Alberto Luini, Maria Carla Gilardi, Anna Maria Colangelo, Lilia Alberghina, Rosa Maria Moresco

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.

Original languageEnglish
Pages (from-to)52017-52031
Number of pages15
JournalOncotarget
Volume7
Issue number32
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Metabolomics
Mass Spectrometry
Metabolic Networks and Pathways
Glutamine
Pharmaceutical Preparations
Neoplasms
Autophagy
Recycling
Glycolysis
Glycine
Serine
Lactic Acid
Cell Survival
Cell Proliferation
Glucose
Food
In Vitro Techniques
Growth
Therapeutics

Keywords

  • Metabolic rewiring
  • Metabolomics-mass-spectrometry
  • Oncogenic-K-ras
  • PET-imaging
  • Tumor

ASJC Scopus subject areas

  • Oncology

Cite this

Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells : A PET imaging and metabolomics-mass-spectrometry study. / Gaglio, Daniela; Valtorta, Silvia; Ripamonti, Marilena; Bonanomi, Marcella; Damiani, Chiara; Todde, Sergio; Negri, Alfredo Simone; Sanvito, Francesca; Mastroianni, Fabrizia; Campli, Antonella Di; Turacchio, Gabriele; Di Grigoli, Giuseppe; Belloli, Sara; Luini, Alberto; Gilardi, Maria Carla; Colangelo, Anna Maria; Alberghina, Lilia; Moresco, Rosa Maria.

In: Oncotarget, Vol. 7, No. 32, 01.08.2016, p. 52017-52031.

Research output: Contribution to journalArticle

Gaglio, D, Valtorta, S, Ripamonti, M, Bonanomi, M, Damiani, C, Todde, S, Negri, AS, Sanvito, F, Mastroianni, F, Campli, AD, Turacchio, G, Di Grigoli, G, Belloli, S, Luini, A, Gilardi, MC, Colangelo, AM, Alberghina, L & Moresco, RM 2016, 'Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study', Oncotarget, vol. 7, no. 32, pp. 52017-52031. https://doi.org/10.18632/oncotarget.10470
Gaglio, Daniela ; Valtorta, Silvia ; Ripamonti, Marilena ; Bonanomi, Marcella ; Damiani, Chiara ; Todde, Sergio ; Negri, Alfredo Simone ; Sanvito, Francesca ; Mastroianni, Fabrizia ; Campli, Antonella Di ; Turacchio, Gabriele ; Di Grigoli, Giuseppe ; Belloli, Sara ; Luini, Alberto ; Gilardi, Maria Carla ; Colangelo, Anna Maria ; Alberghina, Lilia ; Moresco, Rosa Maria. / Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells : A PET imaging and metabolomics-mass-spectrometry study. In: Oncotarget. 2016 ; Vol. 7, No. 32. pp. 52017-52031.
@article{9a2897fd4368490fa30cd765d513e4b6,
title = "Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells: A PET imaging and metabolomics-mass-spectrometry study",
abstract = "Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.",
keywords = "Metabolic rewiring, Metabolomics-mass-spectrometry, Oncogenic-K-ras, PET-imaging, Tumor",
author = "Daniela Gaglio and Silvia Valtorta and Marilena Ripamonti and Marcella Bonanomi and Chiara Damiani and Sergio Todde and Negri, {Alfredo Simone} and Francesca Sanvito and Fabrizia Mastroianni and Campli, {Antonella Di} and Gabriele Turacchio and {Di Grigoli}, Giuseppe and Sara Belloli and Alberto Luini and Gilardi, {Maria Carla} and Colangelo, {Anna Maria} and Lilia Alberghina and Moresco, {Rosa Maria}",
year = "2016",
month = "8",
day = "1",
doi = "10.18632/oncotarget.10470",
language = "English",
volume = "7",
pages = "52017--52031",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "32",

}

TY - JOUR

T1 - Divergent in vitro/in vivo responses to drug treatments of highly aggressive NIH-Ras cancer cells

T2 - A PET imaging and metabolomics-mass-spectrometry study

AU - Gaglio, Daniela

AU - Valtorta, Silvia

AU - Ripamonti, Marilena

AU - Bonanomi, Marcella

AU - Damiani, Chiara

AU - Todde, Sergio

AU - Negri, Alfredo Simone

AU - Sanvito, Francesca

AU - Mastroianni, Fabrizia

AU - Campli, Antonella Di

AU - Turacchio, Gabriele

AU - Di Grigoli, Giuseppe

AU - Belloli, Sara

AU - Luini, Alberto

AU - Gilardi, Maria Carla

AU - Colangelo, Anna Maria

AU - Alberghina, Lilia

AU - Moresco, Rosa Maria

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.

AB - Oncogenic K-ras is capable to control tumor growth and progression by rewiring cancer metabolism. In vitro NIH-Ras cells convert glucose to lactate and use glutamine to sustain anabolic processes, but their in vivo environmental adaptation and multiple metabolic pathways activation ability is poorly understood. Here, we show that NIHRas cancer cells and tumors are able to coordinate nutrient utilization to support aggressive cell proliferation and survival. Using PET imaging and metabolomics-mass spectrometry, we identified the activation of multiple metabolic pathways such as: Glycolysis, autophagy recycling mechanism, glutamine and serine/glycine metabolism, both under physiological and under stress conditions. Finally, differential responses between in vitro and in vivo systems emphasize the advantageous and uncontrolled nature of the in vivo environment, which has a pivotal role in controlling the responses to therapy.

KW - Metabolic rewiring

KW - Metabolomics-mass-spectrometry

KW - Oncogenic-K-ras

KW - PET-imaging

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=84982279709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982279709&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10470

DO - 10.18632/oncotarget.10470

M3 - Article

AN - SCOPUS:84982279709

VL - 7

SP - 52017

EP - 52031

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 32

ER -